[Treatment of relapsed and refractory acute lymphocytic leukemia by modified CAG regimen].
Hao
H
Huang
Li'na
L
Liu
Yuzhang
Y
Liu
Quande
Q
Lin
Qinglan
Q
Zhang
Fengkuan
F
Yu
Yongping
Y
Song
Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Baijun
B
Fang
D015250:Aclarubicin / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012008:Recurrence
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin